Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
8.70
-0.13 (-1.51%)
Mar 25, 2025, 4:00 PM EST - Market closed
Pharming Group Revenue
In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth. Pharming Group had revenue of $92.70M in the quarter ending December 31, 2024, with 14.14% growth.
Revenue (ttm)
$297.20M
Revenue Growth
+21.15%
P/S Ratio
2.01
Revenue / Employee
$778,010
Employees
382
Market Cap
598.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PHAR News
- 12 days ago - Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Pharming Group reports fourth quarter and full year 2024 financial results and provides business update - GlobeNewsWire
- 21 days ago - Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders - GlobeNewsWire
- 6 weeks ago - Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period - GlobeNewsWire
- 2 months ago - Pharming Group to convene Extraordinary General Meeting of Shareholders - GlobeNewsWire
- 2 months ago - Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer - GlobeNewsWire
- 3 months ago - Pharming announces public cash offer to the shareholders of Abliva AB - GlobeNewsWire
- 3 months ago - European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug - Benzinga